An improved stabilization buffer for use in the lyophilization of Neospora and other protozoans is disclosed. Also disclosed is an improved lyophilization method, which includes controlling ice nucleation during the freezing step.

An improved stabilization buffer for use in the lyophilization of Neospora and other protozoans is disclosed. Also disclosed is an improved lyophilization method, which includes controlling ice nucleation during the freezing step.

The present invention is based upon the identification of a number of antigens derived from species of the genus Teladorsagia, which can be used to raise immune responses in animals—particularly those animals susceptible or predisposed to infection by (or with) one or more Teladorsagia species. The antigens may be exploited to provide compositions and vaccines for raising protective immune responses in animals—the protective immune responses serving to reduce, prevent, treat or eliminate Teladorsagia infections/infestations.

The present invention relates to a therapy for treating or preventing several diseases in animals, based on the administration of a highly concentrated avian derived immunoglobulins formulation, obtained from the egg yolk from hens previously hiper-immunized with a vaccine formulation comprising infectious agents or toxins antigens, a light mineral oil and a particulate adjuvant.

The present invention relates to a therapy for treating or preventing several diseases in animals, based on the administration of a highly concentrated avian derived immunoglobulins formulation, obtained from the egg yolk from hens previously hiper-immunized with a vaccine formulation comprising infectious agents or toxins antigens, a light mineral oil and a particulate adjuvant.

The present invention relates to compositions and methods for inducing an adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.

The present invention relates to compositions and methods for inducing an adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.

The present invention provides attenuated Toxoplasma gondii mutants for use as vaccines in the prevention or treatment of cancer.

The present invention provides attenuated Toxoplasma gondii mutants for use as vaccines in the prevention or treatment of cancer.

Provided is a protein having Toxoplasma immunogenicity, the protein being a cyclophilin mutant protein and consisting of the amino acid sequence as shown in SED 2. Further provided is a nucleic acid that may encode a protein having Toxoplasma immunogenicity, which has the nucleic acid sequence as shown in SEQ ID NO. 1. Further provided is a vaccine, which is obtained by double-digesting a Toxoplasma antigen gene and then linking the same to a prokaryotic expression vector such as pET28a, and transforming the same into a prokaryotic expression engineering strain such as BL21(DE3), thereby inducing the high-efficiency expression thereof, wherein the inducing the high-efficiency expression thereof, wherein the purified protein is a soluble protein which maintains specific immunogenicity thereof.